Use of vitelline protein B as a microencapsulating additive
The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations.
1. An encapsulation additive comprising between 0.1 to 90 percent isolated and purified recombinant central portion of the vitelline protein B, one or more active agents, and a cross-linking agent, wherein the cross-linked recombinant portion of the vitelline protein B form an extended release formulation, wherein the central portion of the vitelline protein B comprises amino acids 82-187 of the amino acid sequence selected from the group consisting of SEQ ID NO: 1 or 2 that is non-immunogenic.
2. The additive of claim 1 , wherein the additive slows the release of an active agent to between 1 hour to about 8 hours, between 1 hour to 2 weeks, and between 1 hour to 6 months.
3. The additive of claim 2 , wherein the one or more active agents comprise a pharmaceutical agent, an enzyme, a cytokine, a growth promoting agent, an antibody, an antigen, a vaccine, a live-attenuated pathogen, a heat-killed pathogen, a virus, a bacteria, a fungi, a peptide, a carbohydrate, a nucleic acid, a lipid, mixtures and combinations thereof.
4. The additive of claim 1 , wherein the extended release formulation is encapsulated by coacervation, oil-and-water emulsion, liposomes, spray freezing, spray drying, mixed with alginate or combinations thereof.
5. The additive of claim 1 , wherein the extended release formulation is formulated for administration in a feed to a mammal in need of a therapeutic effective amount of an active agent.
6. The additive of claim 1 , wherein the one or more active agents is selected from the group consisting of protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, antiviral, antifungal, antihelminthic, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, waste product, contaminant, heavy metal, virus, bacterium, Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen, cell, combinations and mixtures thereof, that is encapsulated in a mixed release polymer comprising between about 0.1 to 26 weight percent isolated and purified recombinant central portion of the vitelline protein B or scrambled peptide thereof.
7. An extended release pharmaceutical formulation comprising: one or more active agents microencapsulated in a mixed release polymer and between 0.1 to 26 percent isolated and purified recombinant central portion of the vitelline protein B, one or more active agents, and a cross-linking agent, wherein the cross-linked recombinant portion of the vitelline protein B form an extended release formulation, wherein the central portion of the vitelline protein B comprises amino acids 82-187 of the amino acid sequence selected from the group consisting of SEQ ID NO: 1 or 2 that is non-immunogenic.
8. The formulation of claim 7 , wherein the polymer is selected from the group consisting of cellulose, ethylcellulose, methylcellulose, propylcellulose, methoxypropylcellulose, cellulose nitrate, poly(vinyl alcohol), poly(vinyl chloride), polystyrene, polyethylene, polypropylene, poly(ethylene-co-vinyl acetate), poly(hydroxybutyric acid), poly(hydroxyvalerianic acid-co-hydroxybutyric acid), poly(lactic acid), poly(glycolic acid), poly(lactic acid-co-glycolic acid), poly(epsilon (-caprolactones), poly(epsilon(-caprolactone-co-DL-lactic acid), poly(maleic anhydride), polyamides, gelatin, chitosan, collagen, poly(hydroxyalkyl)-L-glutamines, poly(gamma(-ethyl-L-glutaminate-co-glutamic acid), poly(L-leucine-co-L-aspartic acid), poly(proline-co-glutamic acid), poly(alkyl 2-cyanoacrylates), polyurethanes, poly(methyl methacrylate), poly(methyl methacrylate-co-methacrylic acid) and poly(methacrylate-co-hydroxypropyl methacrylate).
9. The formulation of claim 1 , wherein the additive slows the release of an active agent to between 1 hour to 8 hours, between 1 hour to 2 weeks, and between 1 hour to 6 months.
10. The formulation of claim 7 , wherein the one or more active agents comprise a pharmaceutical agent, an enzyme, a cytokine, a growth promoting agent, an antibody, an antigen, a vaccine, a live-attenuated pathogen, a heat-killed pathogen, a virus, a bacteria, a fungi, a peptide, a carbohydrate, a nucleic acid, a lipid, mixtures and combinations thereof.
11. The formulation of claim 7 , wherein the formulation is encapsulated by extrusion, coacervation, oil-and-water emulsion, liposomes, spray freezing, spray drying, mixed with alginate or combinations thereof.
12. A mixed release pharmaceutical formulation comprising: one or more pharmaceutical agents encapsulated with a mixed release polymer comprising, between 0.1 to 90 percent isolated and purified recombinant central portion of the vitelline protein B, one or more active agents, and a cross-linking agent, wherein the cross-linked recombinant portion of the vitelline protein B form an extended release formulation, wherein the central portion of the vitelline protein B comprises amino acids 82-187 of the amino acid sequence selected from the group consisting, of SEQ ID NO: 1 or 2 that is non-immunogenic.
13. The mixed release formulation of claim 12 , wherein the one or more pharmaceutical agents is selected from wherein the one or more agents may be steroids, respiratory agents, sympathomimetics, local anesthetics, antimicrobial agents, antiviral agents, antifungal agents, antihelminthic agents, insecticides, antihypertensive agents, antihypertensive diuretics, cardiotonics, coronary vasodilators, vasoconstrictors, β-blockers, antiarrhythmic agents, calcium antagonists, anti-convulsants, agents for dizziness, tranquilizers, antipsychotics, muscle relaxants, drugs for Parkinson's disease, respiratory agents, hormones, non-steroidal hormones, antihormones, vitamins, antitumor agents, miotics, herb medicines, antimuscarinic, interfereons, immunokines, cytokines, muscarinic cholinergic blocking agents, mydriatics, psychic energizers, humoral agents, antispasmodics, antidepressant drugs, anti-diabetics, anorectic drugs, anti-allergenics, decongestants, expectorants, antipyretics, antimigrane, anti-malarials, anti-ulcerative, peptides, anti-estrogen, anti-hormone agents, antiulcer agents, anesthetic agent, drugs having an action on the central nervous system, protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, waste product, contaminant, heavy metal, virus, bacterium, Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen, cell, combinations and mixtures thereof.
14. The formulation of claim 12 , wherein the polymer is selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, polysaccharides, carbohydrates, proteins, and combinations thereof.
15. The formulation of claim 12 , wherein the formulation is an immunization comprising one or more antigens selected from protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, interferon, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, explosive, pesticide, chemical warfare agent, biowarfare agent, biohazardous agent, infectious agent, prion, radioisotope, vitamin, heterocyclic aromatic compound, carcinogen, mutagen, narcotic, amphetamine, barbiturate, hallucinogen, waste product, contaminant, heavy metal, virus, bacterium, Salmonella, Streptococcus, Brucella, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia , spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen, cell, combinations and mixtures thereof.